Sam Osman
Sam Osman as President of Enabling Services, responsible for a combination of best-in-class technology and patient access offerings that support Fortrea’s overall mission through innovation and better delivery. Enabling Services include Endpoint Clinical, Fortrea’s digital trials technology platform, decentralized clinical trial offerings and its analytics dashboards as well as post commercial solutions spanning patient access, field nursing and non-commercial specialty pharmacy distribution (FortreaRx™). Sam joined the organization in May 2023 during Fortrea’s spinoff from its parent company, Labcorp.
Sam has two decades of experience leading growth in complex global industries, largely focused on innovation in life sciences. From 2020 to 2023, Sam was Chief Executive Officer of Science and Medicine Group, a proprietary data and intelligence platform company. Previously, he was Chief Executive Officer of Cenduit, an eClinical technology company, which was acquired by IQVIA. Sam was also a founder of a technology business and also served in numerous leadership positions at Quintiles, from 2010 to 2016 including roles in Corporate Development, Partnering and Operations. Prior to joining Quintiles, he was an investment banker with Citi and earlier with Goldman Sachs in New York.
Sam earned his MBA from Carnegie Mellon University, master's degree from London School of Economics and Political Science, and a bachelor's degree in International Business and Biology from the University of Tampa where he was an NCAA athlete. He serves as a Director on several Boards including CREO Inc., Cumulus Neuroscience and LabConnect. Sam has been named a PharmaVoice 100 recipient, top 40 under 40 and 100 Most Influential Life Science Leaders.